Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital
February 28, 2022 8:49 AM ESTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.
The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More
Pacira Pharma (PCRX) Tops Q4 EPS by 9c
February 24, 2022 8:04 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.99, $0.09 better than the analyst estimate of $0.90. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $155.74 million.
GUIDANCE:
Today the company is providing full-year 2022 operating expense guidance as... More
